Range Low Price High Price Comment
30 days $1.83 $2.57 Monday, 29th Apr 2024 CGEN stock ended at $1.98. This is 3.13% more than the trading day before Friday, 26th Apr 2024. During the day the stock fluctuated 4.17% from a day low at $1.92 to a day high of $2.00.
90 days $1.83 $3.03
52 weeks $0.530 $3.03

Historical Compugen Ltd. prices

Date Open High Low Close Volume
Feb 01, 2016 $4.72 $4.77 $4.62 $4.72 73 900
Jan 29, 2016 $4.58 $4.77 $4.56 $4.71 87 200
Jan 28, 2016 $4.58 $4.73 $4.43 $4.58 204 800
Jan 27, 2016 $4.80 $4.84 $4.53 $4.53 194 400
Jan 26, 2016 $4.91 $4.98 $4.76 $4.80 166 100
Jan 25, 2016 $4.83 $5.13 $4.83 $4.91 116 200
Jan 22, 2016 $5.07 $5.16 $4.82 $4.94 140 600
Jan 21, 2016 $4.97 $5.10 $4.85 $4.94 113 800
Jan 20, 2016 $4.79 $5.03 $4.57 $4.96 238 900
Jan 19, 2016 $5.20 $5.20 $4.80 $4.91 163 700
Jan 15, 2016 $4.93 $5.11 $4.85 $5.08 189 100
Jan 14, 2016 $5.19 $5.32 $4.93 $5.20 205 300
Jan 13, 2016 $5.52 $5.68 $5.20 $5.21 309 400
Jan 12, 2016 $5.65 $5.72 $5.30 $5.52 204 400
Jan 11, 2016 $6.00 $6.04 $5.54 $5.55 183 100
Jan 08, 2016 $6.15 $6.20 $5.92 $5.96 90 200
Jan 07, 2016 $6.35 $6.35 $6.01 $6.10 285 200
Jan 06, 2016 $6.87 $6.91 $6.40 $6.53 354 900
Jan 05, 2016 $6.42 $6.92 $6.40 $6.90 228 600
Click to get the best stock tips daily for free!

About Compugen Ltd.

Compugen Ltd. Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients wi... CGEN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT